"Glaucoma 360" Announced by Glaucoma Research Foundation

"Glaucoma 360 promises to bring together a confluence of top tier glaucoma leaders from the fields of medicine, science, business, investment, philanthropy and media with those affected by glaucoma."

San Francisco, CA - September 14, 2011: “Glaucoma 360,” a three-day series of events offering a full-compass view of The Cure, The Catalysts and The Care in glaucoma today, will be presented by the Glaucoma Research Foundation in San Francisco’s Palace Hotel February 2-4, 2012, GRF President and CEO Thomas M. Brunner announced today.

Glaucoma 360 Co-Chairs Adrienne Graves, PhD, and Andrew Iwach, MD, said “Glaucoma 360 promises to bring together a confluence of top tier glaucoma leaders from the fields of medicine, science, business, investment, philanthropy and media with those affected by glaucoma. All proceeds will benefit Glaucoma Research Foundation and help support research, outreach and education.”

Dr. Graves, a member of the Glaucoma Research Foundation (GRF) Board of Directors, and Dr. Iwach, Chair of GRF’s Board of Directors, announced the Advisory Committee for the Glaucoma 360: New Horizons Forum including Anthony P. Adamis, MD, Vice President, Global Head of Ophthalmology, Genentech, Inc.; Paul Chaney, President & CEO, PanOptica; G.A. Cioffi, MD; Alan Crandall MD; Emmett Cunningham MD, PhD, MPH, Partner, Clarus Ventures; Eugene de Juan, MD, Vice Chair, ForSight Labs; Robert Grant, President & CEO Bausch + Lomb Surgical; David Guyer, MD, Partner, SV Life Sciences Advisers, LLC; H. Dunbar Hoskins, Jr., MD, former Exec Vice President American Academy of Ophthalmology; Wende Hutton, General Partner, Canaan Partners; Eliot Lazar, MS, MD, President, elCON Medical; Richard Lindstrom, MD; William J. Link, PhD, Managing Director, Versant Ventures; James Mazzo, President & CEO, Abbott Medical Optics; Gary D. Novack, President, PharmaLogic Development, Inc.; David E. I. Pyott, Chairman, President, and CEO Allergan, Inc.; and Ellen Strahlman, MD, MHSc, Chief Medical Officer, GlaxoSmithKline.

Brunner also announced that Ophthalmology Times will be the Global Media Sponsor and official publication for Glaucoma 360 events. “We are proud to welcome the seasoned and experienced team at Ophthalmology Times,” he said, “to ensure that all the important contributions of Glaucoma 360 participants can be shared around the world.” Ophthalmology Times is a physician-driven publication that disseminates news and information of a clinical, socioeconomic, and political nature in a timely manner for members of the ophthalmic community.

Glaucoma 360 includes:

• At the Glaucoma Research Foundation Annual Benefit, the presentation of GRF’s highest honors, including The Catalyst Award to Richard Lindstrom, MD; the President’s Award to Nobuko Saito Cleary; and The Visionary Award to co-founder of The Byrds and GRF National Spokesperson, Roger McGuinn;

• At the New Horizons Forum, keynote speakers are G. A. Cioffi, MD on the State of Glaucoma Therapy 2012, Martin Wax, MD on Biomarkers for Glaucoma Management, and Wiley A. Chambers MD, Deputy Division Director, FDA on the Glaucoma Drug Approval Process. Presentations will be given by early stage glaucoma companies (drug, device, diagnostics, and drug delivery) and there will be panels of venture capitalists and industry executives speaking on needs and opportunities for better serving glaucoma patients;

• At the Glaucoma Symposium CME, this year’s Shaffer-Hetherington-Hoskins Lecturer is Gregory L. Skuta, MD, President and CEO, Dean McGee Eye Institute and Chair, Department of Ophthalmology, University of Oklahoma College of Medicine.

For information on sponsorships and how to participate in all Glaucoma 360 events, contact E. Carmen Torres, 415.986.3162, ctorres@glaucoma.org.

About Glaucoma Research Foundation

Founded in 1978 and headquartered in San Francisco, Glaucoma Research Foundation is America’s oldest and most experienced institution dedicated solely to its mission: To prevent vision loss from glaucoma by investing in innovative research, education and support with the ultimate goal of finding a cure. GRF funds innovative, results-oriented research and provides educational materials to eye care professionals across the country including our website, glaucoma.org, and patient education booklets. Research initiatives include the multi-year Catalyst For a Cure research consortium and Shaffer Grants for Innovative Glaucoma Research.